This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NitroMed Brass Resign Posts

NitroMed (NTMD) said Tuesday that Michael Loberg, its chief executive and president, and Lawrence Bloch, its chief financial officer, resigned effective immediately. Loberg also resigned as a director.

The Lexington, Mass., drug company provided no reason for the executives' departure, which comes less than three weeks after NitroMed issued a dreadful fourth-quarter financial report .

The company said sales of BiDil -- a treatment for congestive heart failure in African-Americans -- were disappointing. At the time, Loberg and Bloch attributed the weak sales to an inconsistent performance by its sales force and to high copayments charged by managed-care firms. They said they were reorganizing the sales force and stepping up discussions with insurers.

The Food and Drug Administration approved BiDil in June as the first drug endorsed for a specific ethnic group. In July, NitroMed began marketing BiDil, which combines two generic drugs.

NitroMed's stock had been sinking since August, losing about two-thirds of its value. But on Tuesday, shares gained 34 cents, or 3.1%, to $8.07 by midmorning. The stock climbed as high as $8.80.

Loberg, 57, had been CEO and a director since September 1997. Bloch, 39, had been CFO since September 2004.

NitroMed's board said Argeris Karabelas, 52, the company's chairman, has been appointed interim CEO. Karabelas also is a partner of Care Capital LLC, a life-sciences investment firm. Previously, he was CEO of worldwide pharmaceuticals at Novartis (NVS). Karabelas has been NitroMed's chairman since August 2003.

The board said Kenneth Bate will become CFO and chief operating officer. Bate has held executive positions with Millennium Pharmaceuticals (MLNM) and with the former Biogen before it became Biogen Idec (BIIB) through a merger.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs